Bioversys N
BIOV | SW
Overview
Corporate Details
- ISIN(s):
- CH0210362643 (+1 more)
- LEI:
- 894500UFIGC75NPZEZ68
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.bioversys.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioVersys AG is a clinical-stage pharmaceutical company dedicated to developing novel therapeutics for life-threatening bacterial infections and combating the global threat of Antimicrobial Resistance (AMR). The company specializes in the research and development of small molecules that act on novel bacterial targets through innovative modes of action. Its diverse pipeline targets high-priority pathogens as defined by the WHO and CDC. Key clinical programs include Alpibectir, a novel potentiator for multidrug-resistant tuberculosis (MDR-TB), and BV100, which targets serious hospital-acquired infections caused by Acinetobacter baumannii. BioVersys focuses on addressing significant unmet medical needs in AMR to improve patient outcomes.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Bioversys N.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-27 07:00 |
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 21.9 KB | |
| 2025-08-27 02:00 |
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 15.9 KB | |
| 2025-07-02 07:00 |
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
|
English | 21.3 KB | |
| 2025-07-02 02:00 |
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
|
English | 16.1 KB | |
| 2025-06-30 07:00 |
Post-Annual General Meeting Information
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
|
English | 10.5 KB | |
| 2025-06-30 02:00 |
Post-Annual General Meeting Information
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
|
English | 6.9 KB | |
| 2025-06-03 07:00 |
Pre-Annual General Meeting Information
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
|
English | 11.6 KB | |
| 2025-06-03 02:00 |
Pre-Annual General Meeting Information
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
|
English | 11.0 KB | |
| 2025-04-30 00:00 |
Investor Presentation
BioVersys Corporate Presentation
|
English | 3.2 MB | |
| 2025-04-28 07:00 |
Regulatory News Service
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
|
English | 8.5 KB | |
| 2025-04-28 02:00 |
Report Publication Announcement
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
|
English | 7.2 KB | |
| 2025-04-08 07:00 |
Regulatory News Service
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
|
English | 29.7 KB | |
| 2025-03-31 07:00 |
Regulatory News Service
BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE
|
English | 11.6 KB | |
| 2025-03-27 07:00 |
Earnings Release
BIOVERSYS REPORTS CORPORATE HIGHLIGHTS AND KEY FINANCIALS FOR THE FULL YEAR 2024
|
English | 25.6 KB | |
| 2025-03-27 00:00 |
Investor Presentation
Webcast Financial Results 2024 & Business update
|
English | 301.8 KB |
Automate Your Workflow. Get a real-time feed of all Bioversys N filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Bioversys N via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
